Hypercholesterolemia
Conditions
Interventions
investigational material(s)
Generic name etc : K-924
INN of investigational material : -
Therapeutic category code : 3-- Agents affecting metabolism
Dosage and Administration for Investigational mater
Sponsors
Kowa Company, Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients with hypercholesterolemia had to be age 20 years or older at written informed consent (ICF) (2) Patients who have been on a diet and / or exercise regimen more than 12 weeks before the screening (3) Those whose LDL-C (Friedewald formula) at the screening any of the following in the category classification based on Japan Atherosclerosis Society guidelines for prevention Atherosclerotic Cardiovascular Disease 2017 -Low risk of primary prevention : LDL-C => 160 mg / dL -Medium risk of primary prevention : LDL-C => 140 mg / dL -High risk of primary prevention : LDL-C => 120 mg / dL
Exclusion criteria
Exclusion criteria: (1) Patients with a history of myopathy or rhabdomyolysis due to pitavastatin or ezetimibe (2) Patients with a history of hypersensitivity due to pitavastatin or ezetimibe (3) Patients with severe liver damage (Child Pugh Class B or higher) or biliary obstruction (4) Pregnant women, lactating women, women planning to become pregnant or lactating during the study period, or pregnant women who do not use specific contraceptive methods (5) Patients whose CK is 3 times or more of the upper limit of the reference value at screening (6) Patients whose AST and ALT is 2 times or more of the upper limit of the reference value at screening (7) Patients wiht type 1 diabetes or uncontrolled type 2 diabetes as defined HbA1c 8 % or more at screening (8) Patients with uncontrolled hypertension as defined systolic blood pressure of 160 mmHg or more or diastolic blood pressure of 100 mmHg or more at screening (9) Patients with eGFR of less than 30 mL / min / 1.73 m2 at screening or dialysis (10) Patients with heart failure class III or higher according to NYHA cardiac function classification (11) Patients with uncontrolled arrhythmia (12) Patients with uncontrolled metabolic endocrine disease (13) Patients with a history of coronary artery disease or patient with familial hypercholesterolemia (14) Patients with malignant tumors or who are judged to have a high possibility of relapse (15) Patients who have collected 200 mL or more within 4 weeks before screening, 400 mL or more of blood within 12 weeks for males or 16 weeks for females, or within 2 weeks for (Plasma component / platelet component) (16) Persons with a history of severe drug allergy (anaphylactic shock, etc.) (17) Patients who need contraindicated drugs during the study period after obtaining consent (18) Patients with TG of 400 mg / dL or more at screening (19) Patients who have LDL apheresis (20) Patients with malabsorption or history, or who have undergone gastrointestinal surgery (excluding appendectomy, hernia treatment, etc.) that may affect absorption. (21) Patients with Alcohol or drug addiction (22) Patients who participate in other clinical trials within 16 weeks prior to study drug administration and who are administered non-placebo investigational drugs, or who participate in other clinical trials concurrently with this study (23) Patients who have received K-924 (24) Patients who judged to be inappropriate by the Investigator or Investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy % change from baseline in LDL-C (Friedewald formula) (mg / dL) | — |
Secondary
| Measure | Time frame |
|---|---|
| efficacy % change or change from baseline in LDL-C (mg / dL) % change or change from baseline in non-HDL-C (mg / dL) % change or change from baseline in HDL-C (mg / dL) % change or change from baseline in Total Cholesterol (mg / dL) % change or change from baseline in TG (mg / dL) | — |
Countries
Japan
Outcome results
None listed